LPL Financial
EPZM

LPL Financial’s Epizyme, Inc EPZM Stock Holding History

LPL Financial’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,750
Closed -$26K – 4580
2022
Q2 		$26K Sell
17,750
-700
-4% -$514 ﹤0.01% 4317
2022
Q1 		$21K Hold
18,450
– – ﹤0.01% 4121
2021
Q4 		$46K Sell
18,450
-15,028
-45% -$59K ﹤0.01% 4242
2021
Q3 		$171K Buy
33,478
+2,000
+6% +$12.1K ﹤0.01% 4035
2021
Q2 		$262K Buy
31,478
+150
+0.5% +$1.26K ﹤0.01% 3694
2021
Q1 		$273K Buy
31,328
+8,832
+39% +$91.4K ﹤0.01% 3550
2020
Q4 		$244K Buy
22,496
+2,900
+15% +$35.8K ﹤0.01% 3365
2020
Q3 		$234K Buy
19,596
+2,018
+11% +$27K ﹤0.01% 3093
2020
Q2 		$282K Buy
17,578
+1,496
+9% +$26.1K ﹤0.01% 2881
2020
Q1 		$249K Buy
+16,082
New +$345K ﹤0.01% 2651

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

LPL Financial's EPZM Position: Q3 2022 in Review

LPL Financial sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 17,750 shares — an estimated $26K sold.

LPL Financial first reported a position in EPZM in Q1 2020 and held it in 10 quarters. The position peaked at $282K in Q2 2020. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • LPL Financial reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • LPL Financial sold 17,750 Epizyme, Inc shares in Q3 2022, an estimated $26K.
  • LPL Financial first reported a position in Epizyme, Inc in Q1 2020 and held it in 10 quarters.
  • LPL Financial's Epizyme, Inc position peaked at $282K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on LPL Financial's 13F filing for Q3 2022, filed 14 Nov 2022.